Modeling of published quinidine-paroxetine-DDI studies for model evaluation
Within this repository, we distribute a PK-Sim snapshot and a PK-Sim model file containing simulations of all published clinical studies used to evaluate the predictive performance of the quinidine model regarding quinidine-paroxetine-DDIs, including the respective observed data digitized from literature reports. The applied paroxetine model has been published previously [1]. For further details and documentation please refer to [2].
OSP Version 11.0
The model is distributed under the GPLv2 Lincense.
[1] Rüdesheim S, Selzer D, Mürdter T, Igel S, Kerb R, Schwab M, Lehr T. Physiologically based pharmacokinetic modeling to describe the CYP2D6 activity score-dependent metabolism of paroxetine, atomoxetine and risperidone. Pharmaceutics 2022;14(8):1734. DOI: 10.3390/pharmaceutics14081734.
[2] Feick D, Rüdesheim S, Marok FZ, Selzer D, Loer HLH, Teutonico D, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Schwab M, Lehr T. Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug–drug–gene interaction network. CPT Pharmacometrics Syst Pharmacol 2023. DOI: 10.1002/psp4.12981.